Announcements

Stem Cell Network makes first direct biotech investment, awarding $1 million to Montreal-based RejuvenRx

Read Now
Stem Cell Network makes first direct biotech investment, awarding $1 million to Montreal-based RejuvenRx

Stem Cell Network makes first direct biotech investment, awarding $1 million to Montreal-based RejuvenRx

Read Now

Announcements

Stem Cell Network Welcomes Dr. Anthony Flamier to SCN-RDMM Catalyst Grant Program

September 28, 2026 

The Stem Cell Network (SCN) and the Rare Diseases: Models and Mechanisms Network (RDMM) are pleased to announce Dr. Anthony Flamier as the latest recipient of the SCN-RDMM Catalyst Grant.

Announcements

Stem Cell Network makes first direct biotech investment, awarding $1 million to Montreal-based RejuvenRx

September 21, 2026 

New Incubation Investment Award aims to help promising Canadian regenerative medicine companies grow and scale in Canada

Op-Ed

Canada has invested in science. Now it must capture the economic benefits.

September 16, 2026 

The following Op-Ed was co-authored by Cate Murray, Maura Campbell, Jeff Smirle and Penny Walsh and was published in the Hill Times on September 16.

Announcements

New SCN Report Calls for Made-in-Canada Pathway to Move Advanced Therapies to Patients

September 15, 2026 

Canada has the science and expertise to develop breakthrough therapies, but needs a fit-for-purpose pathway to move them from discovery to patient access

Insights Blog

Beyond Muscle Damage: Rethinking Muscle Disease Through the Lens of Regeneration

September 3, 2026 

Ask most people what causes Duchenne muscular dystrophy, and they'll tell you the textbook answer: a genetic mutation leads to the absence of dystrophin, a protein that normally protects muscle fibres from the mechanical stress of contraction.

Announcements

Stem Cell Network launches new national research funding competition in regenerative medicine

July 29, 2026 

July 29, 2026 (Ottawa) – Today the Stem Cell Network (SCN) is pleased to announce the second of two national research funding competitions planned for SCN’s 2025-2029 funding cycle.